

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## HEALTH TECHNOLOGY APPRAISAL PROGRAMME

### Equality impact assessment – Guidance development

#### STA Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma, mediastinal B-cell lymphoma and follicular lymphoma [ID1115]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

#### Consultation

- |   |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

No valid equality issues were raised during the scoping process.
--

- |  |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

The committee noted concerns from clinical experts that axicabtagene ciloleucel may have access issues compared to current treatment as it is only able to be provided at specialist centres. The commissioning expert from NHS England confirmed that treatment would take place in accredited transplant centres which are well distributed across England. The commissioning expert also confirmed that national MDTs would be set up to ensure equality of referral and treatment access. The committee concluded that this was not a specific equality issue.
--

3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these?

The company highlighted that axicabtagene ciloleucel would more likely be used for males and for older people due to the epidemiology of the disease. The committee did not consider this to be a specific equality issue because the recommendation for axicabtagene ciloleucel is for the whole population in the anticipated marketing authorisation, the committee agreed that its recommendations do not have a different impact on people protected by the equality legislation than on the wider population.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

See section 3.24 in the appraisal consultation document

**Approved by Associate Director (name):** Frances Sutcliffe

**Date:** 16/08/2018

## **Final appraisal determination**

(when an ACD issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

No further issues were identified during consultation

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No the recommendations apply to the full population in the marketing authorisation

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No the recommendations apply to the full population in the marketing authorisation

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma, mediastinal B-cell lymphoma and follicular lymphoma

[ID1115]

Issue date: 16 August 2018

to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No the recommendations apply to the full population in the marketing authorisation

5. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?

Yes see section 3.33 of the final appraisal determination

**Approved by Associate Director (name):** ...Frances Sutcliffe.....

**Date:** 29/11/2018